The UK’s nanotechnology powerhouse, Oxonica, has announced its intention to delist from the AIM market, citing the relatively small total market capitalisation of the Company, the small free float, the limited trading volumes in the Company’s shares and the significant direct and indirect costs of compliance with the AIM Rules”
This might also have something to do with it…
Oxonica is also back in court again on the 22nd June for the next round of their long running patent dispute with Neuftec.